Date: 2016-10-05
Type of information: Loan
Company: Scynexis (USA - NJ)
Investors: Solar Capital (USA - CA)
Amount: $ 15 million
Funding type: loan
Planned used: This loan will be used to expand Scynexis' pipeline of indications for SCY-078 and accelerate its other development programs.
Others: * On October 5, 2016, Scynexis announced the closing of a $15 million term loan with Solar Capital, fully funded at close. As of September 30, 2016, Scynexis' preliminary estimate of its cash, cash equivalents and marketable securities totaled $58.4 million, including the $15 million from the loan facility. Armentum Partners acted as financial advisor to SCYNEXIS on the loan facility.
Therapeutic area: Infectious diseases
